Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Populus deltoides pollen is an allergenic extract derived from the pollen of the Eastern Cottonwood tree (Populus deltoides). It is a biologic product used for both diagnosing and treating allergies to this specific pollen. For diagnosis, it is used in skin tests to confirm sensitivity. As a treatment, it is administered via subcutaneous injection as a form of allergy immunotherapy, also known as hyposensitization. The therapy involves repeated injections of the extract to gradually desensitize the patient's immune system, reducing the allergic reaction to cottonwood pollen. This process works by modulating the immune system's response, shifting it away from an allergic IgE-mediated response. The product is marketed by companies like ALK-Abello, Inc. as a non-standardized allergenic extract. [1, 3, 14]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on populus deltoides pollen.